Summary of Key Points
GLP-1 class weight loss drugs, such as semaglutide and tirzepatide, have been selling like hotcakes on e-commerce platforms due to the myth of "lying down and losing weight," but the lack of standardized online prescriptions has led to risks of misuse. The new version of the "Regulations for the Implementation of the Drug Administration Law" came into effect on May 15th, explicitly prohibiting the online retail of drugs with high usage risks. This, combined with the subsequent release of the "Compliance Guidelines for Online Retail of Prescription Drugs," has severely restricted e-commerce sales. This has a significant impact on the GLP-1 market, which relies heavily on e-commerce (with some companies accounting for 60%-80% of their sales online), marking the end of an era of easy profits for the industry. These drugs are not miracle cures; they vary from person to person, and side effects can be severe. The tightened regulation pushes them back from being "weight loss wonder drugs" to prescription medications for treating obesity. Patients now need to obtain prescriptions from hospitals, and pharmaceutical companies must focus on those with genuine medical needs.
I. Sudden Tightening of Regulations: E-commerce Sales of GLP-1 Drugs Are Becoming More Challenging
The new regulations clearly state that drugs with high usage risks cannot be sold online. Additionally, the existing rule from 2022, which prohibits the online sale of injectable medications (except for those used to lower blood sugar), also applies to GLP-1 weight loss drugs. Although e-commerce platforms are making adjustments, there are still loopholes. For example, some sell insulin-based semaglutide products (such as NovoTec) while claiming they can both lower blood sugar and reduce weight, with a guarantee of refund if weight loss is not achieved; others indicate that the product must be picked up in-store but actually allow delivery, requiring patients to provide medical documentation. Industry insiders say that products with a high online presence are the most affected, and the days of easy sales are over.
II. The Myth of "Lying Down and Losing Weight" Drugs: Misuse Can Be Dangerous
Social media has portrayed GLP-1 drugs as miracle solutions, suggesting that one injection can lead to weight loss. However, real-life cases show the dangers: some people have experienced dehydration, ketoacidosis, and even been hospitalized in the ICU after self-injection; others have suffered from severe nausea and vomiting, requiring emergency treatment. The effects of these drugs also vary greatly from person to person. Some find them effective at first but experience weight gain when they stop using them; others have lost significant weight with mesaglutide but had to discontinue it due to side effects. Experts point out that the average weight loss is only about 15% (up to a maximum of 30% for people weighing over 200 pounds), and the drugs should be used in small doses. Relying solely on these drugs without a healthy diet and exercise will not lead to lasting results.
III. E-commerce Was Once the Main Sales Channel, but Now It Has Become a Weakness
In 2023, hospital sales of GLP-1 drugs still dominated (four times that of e-commerce), but by Q4 of 2025, e-commerce sales are expected to reach 1.8 billion yuan, while hospital sales will be 2.1 billion yuan, with a gap of only 15%. Reports show that 82% of e-commerce buyers purchase these drugs for weight loss (not for lowering blood sugar), and keywords like "weight loss" and "lost weight" are more common than "blood sugar," suggesting they are more like consumer goods than prescription medications. Tirzepatide (44%) and semaglutide (40%) account for the majority of e-commerce sales, with domestically produced mesaglutide also making rapid progress. Pharmaceutical companies that relied heavily on e-commerce (60%-80% of their sales) are now facing significant challenges due to the new regulations.
IV. New Regulations Force the Industry to "Return to the Right Path": Drugs Should Be Given to Those Who Really Need Them
The compliance guidelines require real-name purchasing, pharmacist review, and valid prescriptions, ensuring consistent standards for both online and offline sales. Patients must now obtain prescriptions from hospitals, making it more difficult for companies to promote their products. Experts emphasize that the use of these drugs requires strict indications: those with thyroid nodules (grades 4-5) should be cautious, and patients with pancreatitis are prohibited from using them. More than a dozen cases of thyroid cancer have been identified through screening. Pharmaceutical companies can no longer rely on traffic generated by concerns about body image; they must target obese patients with a BMI of ≥28 and adhere to the principles of prescription drug sales.
V. Obesity Is a Disease, Not a "Appearance Issue": Correcting Public Perception Is Crucial
The overweight rate among Chinese adults is 34.3%, and the obesity rate is 16.4%. However, many people have misconceptions: some ignore their BMI issues, while others use drugs due to anxiety about their appearance. Tighter regulation can help curb the misuse of these drugs, but it is also necessary to educate the public that obesity is a chronic disease that can lead to diabetes and cardiovascular diseases. GLP-1 drugs are merely a supplementary tool; the key to effective weight loss is maintaining a healthy lifestyle long-term. This analysis explains policies, market trends, misconceptions, and future directions in simple language, helping the general public understand the reality of GLP-1 weight loss drugs and avoid common pitfalls.